Show simple item record

Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.

dc.contributor.authorRing, A
dc.contributor.authorSestak, I
dc.contributor.authorBaum, M
dc.contributor.authorHowell, Anthony
dc.contributor.authorBuzdar, A
dc.contributor.authorDowsett, M
dc.contributor.authorForbes, J F
dc.contributor.authorCuzick, J
dc.date.accessioned2012-03-22T14:01:49Z
dc.date.available2012-03-22T14:01:49Z
dc.date.issued2011-11-10
dc.identifier.citationInfluence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. 2011, 29 (32):4266-72 J Clin Oncolen_GB
dc.identifier.issn1527-7755
dc.identifier.pmid21990403
dc.identifier.doi10.1200/JCO.2011.35.5545
dc.identifier.urihttp://hdl.handle.net/10541/216296
dc.description.abstractThe Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized trial in which postmenopausal women with early-stage breast cancer were assigned to receive anastrozole, tamoxifen, or the combination. We have conducted a retrospective analysis to examine the effects of comorbidities and age on treatment received, breast cancer-related mortality, and competing causes of mortality.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBreast Neoplasms
dc.subject.meshComorbidity
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNitriles
dc.subject.meshRetrospective Studies
dc.subject.meshRisk
dc.subject.meshTamoxifen
dc.subject.meshTriazoles
dc.titleInfluence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.en
dc.typeArticleen
dc.contributor.departmentSussex Cancer Centre, Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom.en_GB
dc.identifier.journalJournal of Clinical Oncologyen_GB
html.description.abstractThe Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized trial in which postmenopausal women with early-stage breast cancer were assigned to receive anastrozole, tamoxifen, or the combination. We have conducted a retrospective analysis to examine the effects of comorbidities and age on treatment received, breast cancer-related mortality, and competing causes of mortality.


This item appears in the following Collection(s)

Show simple item record